Email: cspc@cspc.cn
News
August 10, 2026
Share:
Previous: VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6063 FOR THE TREATMENT OF RELAPSED, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS OFFICIALLY INITIATED AT THE FI
Next: VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR ANBENITAMAB (KN026) AND DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT ACCEPTED BY
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
